Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R2?, R3, R4 and R5 are as described herein. The compound of formula (I) can be used as a medicament.

Abstract: The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I) wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Abstract: Herein is reported an anti-LNA antibody comprising six HVRs of SEQ ID NO: 42, 44, 46, 51, 53 and 55.

Abstract: Herein is reported a novel variant adeno-associated virus (AAV) capsid protein comprising a heterologous peptide or polypeptide covalently inserted in the GH-loop of the capsid protein relative to a corresponding parental AAV capsid protein, wherein the heterologous peptide or polypeptide comprises a recognition sequence of a transglutaminase and the amino acids residues at positions 452-455 or 453-459 of VP1 of AAV-2 (SEQ ID NO: 65) or at the corresponding positions in the capsid protein of another AAV serotype are replaced by the heterologous peptide or polypeptide or inserted at amino acid position 456.

Abstract: The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5, and R6, are as described herein, composition including the compounds and methods of using the compounds.

Abstract: Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-CD20/anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic agents.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The present invention relates to a process for the preparation of a compound (I), and its solid form, which is a modulator of ?-secretase and may be useful for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

Abstract: A closure system is disclosed for closing an opening of a container. The system includes a stopper member made of an elastic material, a plug portion configured to tightly fit into the container opening and a cover portion configured to abut a boundary surface adjacent to the container opening. A cage member of the system is made of a shape-retentive material, and includes a stopper contacting section, a clipping structure and an intermediate section therebetween. The clipping structure is configured to clip in a corresponding structure of the container. The cage member is configured such that the stopper contacting section applies a pressure to the stopper member cover portion to push the stopper member cover portion onto the boundary surface of the container opening, when the stopper member plug portion is fitted into the container opening and the cage member clipping structure clips in the corresponding structure of the container.

Abstract: The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4a, R4b, and R5 are as described herein, composition including the compounds and methods of using the compounds.

Abstract: The invention relates to novel compounds having the general formula I wherein X, R1, R2, R3 and n are as described herein, composition including the compounds and methods of using the compounds.

Abstract: Methods are disclosed for producing a molecule comprising a polypeptide complex formed by interaction between a first polypeptide comprising a CH3 region comprising a knob modification and a second polypeptide comprising a CH3 region comprising a hole modification.

Abstract: The present invention relates to a method for stabilizing the C3bBb complex, a rapidly decaying component of the alternative pathway of the complement system, and stabilized C3bBb complexes and uses thereof.

Abstract: In one embodiment, a method includes receiving, via graphical user interface of a clinical study tool, a user input including one or more user selected sub-categories from one or more categories associated with a clinical study; selecting, for each clinical-study metric of a plurality of clinical-study metrics, a model from either a baseline model or one of a plurality of category-specific machine-learning models to predict the clinical-study metric using a model performance lookup table; predicting values for the plurality of clinical-study metrics using corresponding selected models; generating one or more predictions for assessing the clinical study based on the predicted values for the plurality of clinical-study metrics; and displaying, via the graphical user interface of the clinical study tool, the one or more predictions for assessing the clinical study.

Abstract: The invention relates to a chromatography method of producing a target elution volume comprising a first and a second target protein. The method includes providing a cation exchange chromatography column; applying a protein solution on the column, the protein solution comprising the first target protein, a second target protein and optionally one or more further proteins; inputting an optimization criterion; computing chromatography simulations for computing an elution buffer salt concentration adapted to provide a target elution volume matching the optimization criterion best; computing the pooling borders of the target elution volume as a function of at least the computed salt concentration and the input optimization criterion; applying an elution buffer having the computed salt concentration on the chromatography column; performing the elution; and collecting the computed target elution volume.

Abstract: The present invention relates to combination therapies employing an anti-CD20/anti-CD3 bispecific antibody in combination with an anti-CD19/anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).

Abstract: Methods of extracting information about protein sequence modifications in a protein are disclosed. Protein data derived from mass spectrometry measurements performed on peptides from at least two enzymatic digests is received. Candidate sequence modifications are identified. A subset of the candidate sequence modifications that have a higher average probability of representing true sequence modifications than the rest of the candidate sequence modifications are determined. The determination of the subset of candidate sequence modifications comprises a step of selecting candidate sequence modifications dependent on the candidate sequence modifications being at amino acid sequence positions that are covered by at least two different peptide species that each contain the modification.

Abstract: The present invention provides novel compounds having the general formula: (I) wherein R1 to R6, X, Y, and Z are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to anti-VEGF/anti-PDGF-B antibodies and methods of using the same.